Ultragenyx Pharmaceutical’s Acquisition Of Shares in Arcturus Therapeutics

Shearman & Sterling represented Ultragenyx Pharmaceutical in purchasing 600,000 additional shares of common stock of Arcturus Therapeutics at $16.00 per share consistent with the Equity Purchase…